View Past PerformanceCipher Pharmaceuticals バランスシートの健全性財務の健全性 基準チェック /66Cipher Pharmaceuticalsの総株主資本は$132.7M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$153.3Mと$20.5Mです。 Cipher Pharmaceuticalsの EBIT は$20.1Mで、利息カバレッジ比率27です。現金および短期投資は$6.4Mです。主要情報0%負債資本比率US$0負債インタレスト・カバレッジ・レシオ27x現金US$6.41mエクイティUS$132.75m負債合計US$20.53m総資産US$153.28m財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 30Cipher Pharmaceuticals Inc. to Report Q1, 2026 Results on May 07, 2026Cipher Pharmaceuticals Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026お知らせ • Apr 21Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 18, 2026Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 18, 2026. Location: ontario, toronto Canadaお知らせ • Mar 05Cipher Pharmaceuticals Inc. to Report Q4, 2025 Results on Mar 12, 2026Cipher Pharmaceuticals Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Mar 12, 2026お知らせ • Jan 29Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba™? (Spinosad)Cipher Pharmaceuticals Inc. announced that Health Canada has accepted for review Cipher's new drug submission ("NDS") for Natroba™? (Spinosad), for the treatment of head lice and scabies. Natroba™? (Spinosad) is widely recognized as one of the most effective treatments for the two parasitic indications of head lice and sc babies in the U.S. It is superior to the widely used permethrin 1% for treating head lice and is the only treatment in the U.S. that meets the FDA's criteria for a " complete cure" (elimination of all signs and symptoms) in eradicating sc babies infestations with a single application. Cipher acquired Natroba™? (spinosad) in July 2024, and since acquisition has marketed and distributed the product in the United States ("U.S.) market, through its commercial infrastructure.お知らせ • Oct 30Cipher Pharmaceuticals Inc. to Report Q3, 2025 Results on Nov 06, 2025Cipher Pharmaceuticals Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025お知らせ • Aug 28Cipher Pharmaceuticals Inc. Announces the Passing of Board Director and Chairman of Audit Committee Harold M. WolkinCipher Pharmaceuticals Inc. announced the passing of Harold M. Wolkin, a valued member of the Company's Board of Directors and Chairman of the Audit Committee. Mr. Wolkin was a very active member of the Board and his deep understanding of the capital markets and unwavering commitment to the Company's growth and governance were tremendously valuable to the Company. During his tenure, he played a vital role in guiding strategic initiatives, supporting management, and representing the Company and its shareholders with integrity. Harold was a very well-known and highly respective member of the Canadian capital markets community and he will truly be missed by those that knew him.お知らせ • Jul 29Cipher Pharmaceuticals Inc. to Report Q2, 2025 Results on Aug 07, 2025Cipher Pharmaceuticals Inc. announced that they will report Q2, 2025 results at 4:00 PM, US Eastern Standard Time on Aug 07, 2025お知らせ • May 03Cipher Pharmaceuticals Inc. to Report Q1, 2025 Results on May 08, 2025Cipher Pharmaceuticals Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025お知らせ • Apr 09Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025. Location: ontario, toronto Canadaお知らせ • Mar 12Cipher Pharmaceuticals Inc. to Report Q4, 2024 Results on Mar 18, 2025Cipher Pharmaceuticals Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Mar 18, 2025お知らせ • Nov 04Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024Cipher Pharmaceuticals Inc. announced that they will report Q3, 2024 results After-Market on Nov 07, 2024お知らせ • Oct 08Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business OfficerCipher Pharmaceuticals Inc. announced the appointment of Hamed Ghanei as Chief Business Officer. Dr. Ghanei has over 15 years of experience in specialty pharmaceuticals, venture funds, and healthcare investment banking. Throughout his career, he has led the evaluation of over 500 licensing and M&A opportunities and has been involved in five commercial product launches. He has successfully negotiated over 20 transactions with total value exceeding $1 billion. Dr. Ghanei holds a B.Sc. from the University of Waterloo, a M.Sc. in Microbiology and Biochemistry from the University of Guelph, and a Ph.D. in Medical Biophysics from the University of Toronto.お知らせ • Aug 09+ 1 more updateCipher Pharmaceuticals Inc. Announces CFO ChangesEffective August 10, 2024, and as a result of the Natroba Acquisition, Cipher Pharmaceuticals Inc.'s Chief Financial Officer, Bryan Jacobs, will assume the title of President of the Company. His mandate will be to manage the transition and integration of the U.S. operations and commercial sales team. The Company's Vice President, Finance, Ryan Mailling, has in turn been appointed as the Chief Financial Officer of the Company, taking over from Mr. Jacobs.お知らせ • Aug 02Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024Cipher Pharmaceuticals Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024お知らせ • Apr 09Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024.お知らせ • Mar 09Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024Cipher Pharmaceuticals Inc. announced that they will report Q4, 2023 results After-Market on Mar 14, 2024お知らせ • Oct 28Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023Cipher Pharmaceuticals Inc. announced that they will report Q3, 2023 results on Nov 09, 2023お知らせ • Sep 06Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares.Cipher Pharmaceuticals Inc. (TSX:CPH) announces a share repurchase program. Under the substantial issuer bid, the company will repurchase up to CAD 6 million worth of its outstanding shares. The shares will be tendered at a price of not less than CAD 3.95 per share and not more than CAD 4.75 per share. The company plans to fund the offer from available cash on hand. The shares purchased under the offer will be cancelled. If the aggregate cost to purchase the tendered shares exceeds $6 million, the company will accept such shares on a pro-rata basis after giving effect to “odd lot” tenders, which will not be subject to pro-ration. The bid will expire on October 11, 2023, unless extended or withdrawn.お知らせ • Jul 29Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023Cipher Pharmaceuticals Inc. announced that they will report Q2, 2023 results on Aug 10, 2023お知らせ • May 05Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023Cipher Pharmaceuticals Inc. announced that they will report Q1, 2023 results on May 11, 2023お知らせ • Feb 14Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023On February 10, 2022, the Board of Directors of Cipher Pharmaceuticals Inc. declared a quarterly dividend of $0.0.01875 per share to shareholders of record on February 21, 2023, payable on or about February 28, 2023.財務状況分析短期負債: CPHR.Fの 短期資産 ( $25.5M ) が 短期負債 ( $20.4M ) を超えています。長期負債: CPHR.Fの短期資産 ( $25.5M ) が 長期負債 ( $165.0K ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: CPHR.Fは負債がありません。負債の削減: CPHR.F 5 年前には負債がありませんでした。債務返済能力: CPHR.Fには負債がないため、営業キャッシュフロー でカバーする必要はありません。インタレストカバレッジ: CPHR.Fには負債がないため、利息支払い の負担は問題になりません。貸借対照表健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 06:12終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cipher Pharmaceuticals Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関David NovakATB Cormark Historical (Cormark Securities)Tania Armstrong-WhitworthCanaccord GenuityPrakash GowdCIBC Capital Markets5 その他のアナリストを表示
お知らせ • Apr 30Cipher Pharmaceuticals Inc. to Report Q1, 2026 Results on May 07, 2026Cipher Pharmaceuticals Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026
お知らせ • Apr 21Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 18, 2026Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 18, 2026. Location: ontario, toronto Canada
お知らせ • Mar 05Cipher Pharmaceuticals Inc. to Report Q4, 2025 Results on Mar 12, 2026Cipher Pharmaceuticals Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Mar 12, 2026
お知らせ • Jan 29Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba™? (Spinosad)Cipher Pharmaceuticals Inc. announced that Health Canada has accepted for review Cipher's new drug submission ("NDS") for Natroba™? (Spinosad), for the treatment of head lice and scabies. Natroba™? (Spinosad) is widely recognized as one of the most effective treatments for the two parasitic indications of head lice and sc babies in the U.S. It is superior to the widely used permethrin 1% for treating head lice and is the only treatment in the U.S. that meets the FDA's criteria for a " complete cure" (elimination of all signs and symptoms) in eradicating sc babies infestations with a single application. Cipher acquired Natroba™? (spinosad) in July 2024, and since acquisition has marketed and distributed the product in the United States ("U.S.) market, through its commercial infrastructure.
お知らせ • Oct 30Cipher Pharmaceuticals Inc. to Report Q3, 2025 Results on Nov 06, 2025Cipher Pharmaceuticals Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025
お知らせ • Aug 28Cipher Pharmaceuticals Inc. Announces the Passing of Board Director and Chairman of Audit Committee Harold M. WolkinCipher Pharmaceuticals Inc. announced the passing of Harold M. Wolkin, a valued member of the Company's Board of Directors and Chairman of the Audit Committee. Mr. Wolkin was a very active member of the Board and his deep understanding of the capital markets and unwavering commitment to the Company's growth and governance were tremendously valuable to the Company. During his tenure, he played a vital role in guiding strategic initiatives, supporting management, and representing the Company and its shareholders with integrity. Harold was a very well-known and highly respective member of the Canadian capital markets community and he will truly be missed by those that knew him.
お知らせ • Jul 29Cipher Pharmaceuticals Inc. to Report Q2, 2025 Results on Aug 07, 2025Cipher Pharmaceuticals Inc. announced that they will report Q2, 2025 results at 4:00 PM, US Eastern Standard Time on Aug 07, 2025
お知らせ • May 03Cipher Pharmaceuticals Inc. to Report Q1, 2025 Results on May 08, 2025Cipher Pharmaceuticals Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025
お知らせ • Apr 09Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025. Location: ontario, toronto Canada
お知らせ • Mar 12Cipher Pharmaceuticals Inc. to Report Q4, 2024 Results on Mar 18, 2025Cipher Pharmaceuticals Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Mar 18, 2025
お知らせ • Nov 04Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024Cipher Pharmaceuticals Inc. announced that they will report Q3, 2024 results After-Market on Nov 07, 2024
お知らせ • Oct 08Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business OfficerCipher Pharmaceuticals Inc. announced the appointment of Hamed Ghanei as Chief Business Officer. Dr. Ghanei has over 15 years of experience in specialty pharmaceuticals, venture funds, and healthcare investment banking. Throughout his career, he has led the evaluation of over 500 licensing and M&A opportunities and has been involved in five commercial product launches. He has successfully negotiated over 20 transactions with total value exceeding $1 billion. Dr. Ghanei holds a B.Sc. from the University of Waterloo, a M.Sc. in Microbiology and Biochemistry from the University of Guelph, and a Ph.D. in Medical Biophysics from the University of Toronto.
お知らせ • Aug 09+ 1 more updateCipher Pharmaceuticals Inc. Announces CFO ChangesEffective August 10, 2024, and as a result of the Natroba Acquisition, Cipher Pharmaceuticals Inc.'s Chief Financial Officer, Bryan Jacobs, will assume the title of President of the Company. His mandate will be to manage the transition and integration of the U.S. operations and commercial sales team. The Company's Vice President, Finance, Ryan Mailling, has in turn been appointed as the Chief Financial Officer of the Company, taking over from Mr. Jacobs.
お知らせ • Aug 02Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024Cipher Pharmaceuticals Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024
お知らせ • Apr 09Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024.
お知らせ • Mar 09Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024Cipher Pharmaceuticals Inc. announced that they will report Q4, 2023 results After-Market on Mar 14, 2024
お知らせ • Oct 28Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023Cipher Pharmaceuticals Inc. announced that they will report Q3, 2023 results on Nov 09, 2023
お知らせ • Sep 06Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares.Cipher Pharmaceuticals Inc. (TSX:CPH) announces a share repurchase program. Under the substantial issuer bid, the company will repurchase up to CAD 6 million worth of its outstanding shares. The shares will be tendered at a price of not less than CAD 3.95 per share and not more than CAD 4.75 per share. The company plans to fund the offer from available cash on hand. The shares purchased under the offer will be cancelled. If the aggregate cost to purchase the tendered shares exceeds $6 million, the company will accept such shares on a pro-rata basis after giving effect to “odd lot” tenders, which will not be subject to pro-ration. The bid will expire on October 11, 2023, unless extended or withdrawn.
お知らせ • Jul 29Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023Cipher Pharmaceuticals Inc. announced that they will report Q2, 2023 results on Aug 10, 2023
お知らせ • May 05Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023Cipher Pharmaceuticals Inc. announced that they will report Q1, 2023 results on May 11, 2023
お知らせ • Feb 14Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023On February 10, 2022, the Board of Directors of Cipher Pharmaceuticals Inc. declared a quarterly dividend of $0.0.01875 per share to shareholders of record on February 21, 2023, payable on or about February 28, 2023.